Sensitivity and specificity of four assays to detect human T-lymphotropic virus type I or type I/II antibodies

Transfusion

Volumn 36, Issue 4, 1996, Pages 344-346

  Vrielink, H ^a   Reesink, H W ^a   Zaaijer, H L ^a   Van Der Poel, C L ^a   Cuypers, H T M ^a   Lelie, P N ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY SPECIFICITY; ARTICLE; BIOASSAY; BLOOD TRANSFUSION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; SCREENING TEST; SEROCONVERSION; VIRUS DETECTION; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0029985363     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.36496226150.x     Document Type: Article

References (17)

1. Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group. Ann Intern Med 1993;118:448-54.
2. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984;46:245-53.
3. Inaba S, Sato H, Okochi K, et al. Prevention of transmission of human T-lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus. One-year experience. Transfusion 1989;29:7-11.
4. Anderson DW, Epstein JS, Lee TH, et al. Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors. Blood 1989;74:2585-91.
5. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990;322:383-8.
6. Murphy EL, Fridey J, Smith JW, et al. High prevalence of HTLV-associated myelopathy (HAM) among subjects infected with HTLV-I and -II (abstract). Transfusion 1993;33(Suppl):68S.
7. Dodd RY. Adverse consequences of blood transfusion: quantitative estimates. In: Nance ST, ed. Blood supply: risks, perceptions and prospects for the future. Bethesda: American Association of Blood Banks, 1994:1-24.
8. Hjelle B, Mills R, Mertz G, Swenson S. Transmission of HTLV-II via blood transfusion. Vox Sang 1990;59:119-22.
9. Kira JI, Koyanagi Y, Hamakado T, et al. HTLV-II in patients with HTLV-I-associated myelopathy (letter). Lancet 1991;338:64-5.
10. Hjelle B, Appenzeller O, Mills R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992;339:645-6.
11. Murphy EL, Engstrom JW, Miller K, et al. HTLV-II associated myelopathy in 43-year-old woman. Lancet 1993;341:757-8.
12. Reesink HW, Vrielink H, Zaaijer HL, et al. Evaluation of a new HTLV-I/II PCR: Amplicor HTLV-I/II test (abstract). Transfusion 1994;34(Suppl):48S.
13. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 1991;337:1435-9.
14. Finney DJ. Probit analysis. Cambridge, UK: Cambridge University Press, 1971.
15. Hjelle B. Human T-cell leukemia/lymphoma viruses. Life cycle, pathogenicity, epidemiology, and diagnosis. Arch Pathol Lab Med 1991;115:440-50.
16. Wiktor SZ, Pate EJ, Weiss SH, et al. Sensitivity of HTLV-I antibody assays for HTLV-II (letter). Lancet 1991;338:512-3.
17. Hjelle B, Wilson C, Cyrus S, et al. Human T-cell leukemia virus type II infection frequently goes undetected in contemporary US blood donors. Blood 1993;81:1641-4.